REHABILICARE INC Form 10-Q May 15, 2002

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

	FORM 1)-Q	
 X	QUARTERLY REPORT PURSUANT	TO SECTION 13 OR 1	5(d) OF THE
	SECURITIES EXCHANGE ACT O	7 1934	
	For the Quarterly period 1	Ended March 31, 200	2
	OR		
	TRANSITION REPORT PURSUAN	T TO SECTION 13 OR	15(d) OF THE
	SECURITIES EXCHANGE ACT OF	F 1934	
	For the transition period	from	to
(Exa	Commission File REHABILICA act name of registrant as :	RE INC.	arter)
MINNES (State or other incorporation or	jurisdiction of		985318 Identification No.)
	1811 OLD HIG NEW BRIGHTON, MII (Address of principal e	NESOTA 55112	
(Re	(651) 631- egistrant's telephone numbe		code)
to be filed by Se the preceding 12 required to file	mark whether the registrated action 13 or 15(d) of the 3 months (or for such shorted such reports), and (2) has the past 90 days.	Securities Exchange er period that the	Act of 1934 during Registrant was
Yes X No			
	per of shares outstanding of May 3, 2002 was:	of each of the issu	er's classes of
COMMON STOCK, \$.1	10 PAR VALUE		10,935,118 SHARES

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

The following Quarterly Report on Form 10-Q contains various "forward looking statements" within the meaning of federal securities laws. These forward looking statements represent management's expectations or beliefs concerning future events, including statements regarding anticipated product introductions; changes in markets, customers and customer order rates; changes in third party reimbursement rates; expenditures for research and development; growth in revenue; taxation levels; and the effects of pricing decisions. When used in this 10-Q, the words "anticipate," "believe," "expect," "estimate" and similar expressions are generally intended to identify forward-looking statements. These and other forward looking statements made by the Company must be evaluated in the context of a number of factors that may affect the Company's financial condition and results of operations, including, but not limited to, the following:

- Like many medical device companies, the Company has a large balance of uncollected receivables. If it cannot collect an amount of receivables that is consistent with historical collection rates, it might be required to charge off a portion of uncollected receivables.
- In the United States, the Company's products are subject to reimbursement by private and public healthcare reimbursement agencies that impose limits on reimbursement and strict rules on applications for reimbursement. Changes in the rates, eligibility or requirements for reimbursement, or failure to comply with reimbursement requirements, could cause a reduction in income from operations or fines or both.
- The Company maintains significant amounts of inventory on consignment at clinics for distribution to patients. It may not be able to completely control losses of this inventory and, if inventory losses are not consistent with historical experience, it might be required to write off a portion of the carrying value of inventory.
- The clinical effectiveness of the Company's electrotherapy products has periodically been challenged. Publicity about the effectiveness of electrotherapy for pain relief or other clinical applications could negatively impact revenue and income from operations.
- The Company has periodically been the subject of litigation that has caused it additional expense, including a Medicare whistleblower suit settled in 2000 for approximately \$1.6 million and, currently, a \$2.3 million product liability suit that proceeded to a default judgment without the Company's knowledge. The costs of these actions, and other actions that may arise, have negatively affected, and may continue to negatively affect, the Company's operating results.

2

PART I - FINANCIAL INFORMATION

Included herein is the following unaudited condensed financial information:

Consolidated Balance Sheets as of March 31, 2002 and June 30, 2001 $\,$

Consolidated Statements of Operations for the three months and nine months ended March 31, 2002 and 2001

Consolidated Statements of Cash Flows for the nine months ended March 31, 2002 and 2001

Notes to Consolidated Financial Statements

3

REHABILICARE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

	March 31, 2002
ASSETS	
Current Assets:	
Cash and cash equivalents	\$ 2,067,383
Receivables, less reserve for uncollectible accounts of \$9,429,162	. , , , , , , , , , , , , , , , , , , ,
and \$8,062,378	21,323,694
Inventories -	
Raw materials	2,326,039
Work in process	55,654
Finished goods	6,437,562
Deferred tax assets	4,075,317
Prepaid expenses	1,339,218
Total current assets	37,624,867
Property, plant and equipment, net	4,742,232
Intangible assets, net	11,050,497
Deferred tax assets	471,015
Other assets	119,675
	\$ 54,008,286
LIABILITIES AND STOCKHOLDERS' EQUITY	
Current Liabilities:	
Note payable	\$ 400,000
Current maturities of long-term debt	2,491,870
Accounts payable	2,514,437

Accrued liabilities - Payroll Commissions Income taxes Other	564,656 341,109 1,635,513 4,760,685
Total current liabilities	12,708,270
Long-Term Liabilities: Long term-debt Deferred tax liabilities	7,881,322 381,368
Total liabilities	20,970,960
Stockholders' Equity: Common stock, \$.10 par value: 25,000,000 shares authorized; issued and outstanding 10,927,618 and 10,792,060 shares, respectively Preferred stock, no par value; 5,000,000 shares authorized; none issued and outstanding Additional paid-in capital Less note receivable from officer/stockholder Unearned compensation on restricted stock Accumulated other non-owner changes in equity Retained earnings	1,092,762 21,761,613 (168,417) (105,000) (180,421) 10,636,789
Total stockholders' equity	33,037,326
	\$ 54,008,286 =========

.

REHABILICARE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended March 31		Nine Mont Marc	
	2002	2001	2002	
Net sales and rental revenue	\$ 17,777,430	\$ 15,171,676	\$ 51,409,302	
Cost of sales and rentals	5,703,410	4,822,818	16,880,368	
Gross profit	12,074,020	10,348,858	34,528,934	
Operating expenses:				
Selling, general and administrative	9,687,439	8,048,582	26,180,229	
Research and development	473,381	493,643	1,575,644	
Total operating expenses	10,160,820	8,542,225	27,755,873	

Income from operations	1,913,200	1,806,633	6,773,061
Other income (expense): Interest expense Other	(144,380) 3,911	(313,035) 14,376	(559,580) 14,237
Income before income taxes	1,772,731	1,507,974	6,227,718
Income tax provision	744,000	646,000	2,616,000
Net income		\$ 861,974 =======	\$ 3,611,718
Net income per common and common equivalent share			
Basic		\$ 0.08	
Diluted	\$ 0.09	\$ 0.08	\$ 0.32
Weighted average number of shares outstanding			
Basic	10,907,755	10,788,277	10,849,310
Diluted	11,307,273	10,844,363	11,189,131

5

REHABILICARE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended March 31	
	2002	2
Operating Activities:		
Net income Adjustments to reconcile net income to net cash	\$ 3,611,718	\$ 2 , 8
provided by operating activities Depreciation and amortization	1,208,951	1,7

Amortization of unearned compensation Change in long-term portion of deferred taxes	81,563 13,769	1
Change in current assets and liabilities		
Receivables	(2,144,051)	1,6
Inventories	(30,278)	2
Prepaid expenses	909,033	(6
Accounts payable	(1,634,172)	(1,9
Accrued liabilities	1,375,925	(1,5
Net cash provided by operating activities	3,392,458	2,4
Investing Activities:	(670 300)	(2
Purchases of property and equipment	(670,308)	(2
Change in other assets, net	8 , 089	(4
Net cash used in investing activities	(662,219)	(7
Financing Activities:		
Principal payments on long-term obligations	(2,469,523)	(2,3
Proceeds from (payments on) line of credit, net	400,000	(1
Proceeds from exercise of stock options	242,946	3
Proceeds from employee stock purchase plan	111,845	1
Net cash used in financing activities	(1,714,732)	(2,0
Effect of exchange rates on cash and cash equivalents	292 , 265	(3
Net increase (decrease) in cash and cash equivalents	1,307,772	(6
Cash and Cash Equivalents at Beginning of Period	759 , 611	2 , 2
Cash and Cash Equivalents at End of Period	\$ 2,067,383 ========	\$ 1,6 ====
Supplemental Cash Flow Information		
Interest paid	\$ 554 , 378	\$ 1,0
Interest pard	========	=====
Income taxes paid	\$ 2,662,220	\$ 2 , 5
-		· ·

6

REHABILICARE INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2002

1. Accounting Policies

The amounts set forth in the preceding financial statements are unaudited as of and for the periods ended March 31, 2002 and 2001 but, in the opinion of management, reflect all adjustments (consisting only of normal recurring

adjustments) necessary for a fair statement of the results for the periods presented. Such results are not necessarily indicative of results for the full year. The accompanying financial statements of the Company should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2001 included in the Company's Annual Report on Form 10-K.

Certain previously reported amounts have been reclassified to conform to classifications adopted in fiscal year 2002. These reclassifications had no effect on net income, cash flows or stockholders' equity.

2. Recently Issued Accounting Standards

In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, Business Combinations, and No. 142, Goodwill and Other Intangible Assets, effective for fiscal years beginning after December 15, 2001, with early adoption permitted for companies with fiscal years beginning after March 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the statements. Other intangible assets will continue to be amortized over their useful lives.

The Company adopted the new rules on accounting for goodwill and other intangible assets beginning in the first quarter of fiscal 2002. Amounts previously recorded as separately identifiable intangibles for acquired work force and customer list have been subsumed to goodwill in accordance with FAS 141, increasing goodwill by \$1.6 million as of the date of adoption. Effective with the July 1, 2002 adoption of FAS 142, goodwill is no longer amortized but is instead subject to an annual impairment test. The transitional impairment test conducted in connection with the adoption of FAS 142 resulted in no required provision for impairment.

Goodwill and other intangible assets resulting from acquisitions of business and the formation of the Company consist of the following:

	June 30, 2001	March 31, 2002
Goodwill	\$11,504,520	\$11,504,520
Less accumulated amortization	1,671,430	1,671,430
Net goodwill	9,833,090	9,833,090
Other intangible assets:	1,783,686	1,783,686
Less accumulated amortization	366,015	566,249
Net other intangible assets	1,417,671	1,217,407
Total intangible assets, net	\$11,250,761	\$11,050,497
	========	========

7

With the adoption of FAS 142, the Company ceased amortization of goodwill as of July 1, 2001. The following table presents the results of the Company for all periods presented on a comparable basis:

		Nine Months	Ended	March 31
		2002		2001
Reported net income attributed to				
common shareholders Add back goodwill amortization, net of	\$	3,611,718	\$	2,806,237
tax provision				354,459
Adjusted net income attributed to common shareholders	\$	3,611,718	\$	3,160,696
***************************************	==	=======	===	
Diluted net income per share: Reported net income attributed to				
common shareholders	\$.32	\$.26
Goodwill amortization				.03
Adjusted net income attributed to				
common shareholders	\$.32		.29

3. Note Payable and Long Term Debt

The Company has a \$20,000,000 credit facility which provides for both term and revolving borrowings at varying rates based either on the bank's prime rate or LIBOR. As of March 31, 2002, there were borrowings outstanding of \$8,597,000 under the long-term note and \$400,000 under the revolving credit line.

Borrowings under the credit facility are secured by substantially all of the U.S. assets of the Company other than those pledged as collateral on previously existing lease or mortgage obligations. The interest rate on the term loan was 3.875% at March 31, 2002 and the weighted average rate on borrowings under the revolving line of credit was 5.65%.

The Company was in compliance with all financial covenants of its credit agreement as of March 31, 2002 and for the period then ended.

8

4. Segment Information

Rehabilicare and its consolidated subsidiaries operate in one reportable segment, the manufacture and distribution of electromedical pain management, rehabilitation and sports training products. The Company's chief operating decision makers use consolidated results to make operating and strategic decisions. Net revenue from the United States and foreign sources (primarily Europe) was as follows:

		Months Ended h 31
	2002	2001
U.S. revenue Foreign revenue	\$34,180,374 17,228,928	\$33,184,315 12,083,725
	\$51,409,302	\$45,268,040

Net revenue by product line was as follows:

	For the Nine Marc	Months Ended
	2002	2001
Rehabilitation products Pain management Consumer Products Accessories and supplies	\$10,707,791 10,469,977 12,477,936 17,753,598	\$ 9,194,245 10,571,689 8,592,509 16,909,597
	\$51,409,302	\$45,268,040

During the first nine months of fiscal 2002 and 2001, one customer accounted for approximately 15% and 13%, respectively, of consolidated revenue. This customer represented approximately 9% of total accounts receivable at March 31, 2002.

9

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The Company designs, manufactures and distributes electrotherapy products used for pain management, rehabilitation and sports training. Its products are used in clinical, home health care, sports medicine and occupational medicine applications. It also distributes other medical products used in related applications. The Company operates in one business segment, distributing its products through sales to medical product dealers and distributors, sport shops and, in the

United States and the United Kingdom, through direct rental or sale to patients.

The direct rental or sale approach in the United States involves placing electrotherapy units with physicians, physical therapists and other health care providers who then refer those units to patients after determining an appropriate treatment regimen. Units are left on consignment with the health care providers for such referral. The Company then bills the patient or the patient's insurance carrier directly after being notified that a unit has been prescribed and provided to the patient. The Company takes responsibility for subsequent patient follow-up, including extension of the rental period; sale of the unit, if appropriate, and sale of additional supplies required for continued use of the electrotherapy units. This distribution approach requires the Company to maintain significant investments in inventories and receivables.

10

RESULTS OF OPERATIONS

The following table sets forth information from the statements of operations as a percentage of revenue for the periods indicated:

	Three Months Ended March 31		Nine Months Ended March 31	
	2002	2001	2002	2001
Net sales and rental revenue	100.0%	100.0%	100.0%	100.0%
Cost of sales and rentals	(32.1)	(31.8)	(32.8)	(31.4)
Gross profit	67.9	68.2	67.2	68.6
Operating expenses - Selling, general and administrative Research and development Total operating expenses	(2.7)	(3.3)	(3.1)	(2.9)
Income from operations	10.8	11.9	13.2	13.1
Other income (expense), net	(0.8)	(1.9)	(1.1)	(2.2)
Income tax provision	(4.2)	(4.3)	(5.1)	(4.7)
Net income	5.8 =====	5.7 =====		6.2

Revenue was \$17,777,000 for the third quarter of fiscal 2002, a 17% increase from \$15,172,000 for the third quarter of fiscal 2001. Revenue for the nine months ended March 31, 2002 increased 14% to \$51,409,000 from \$45,268,000 for the first nine months of fiscal 2001. The largest component of those increases was the Company's Compex operation where revenue increased 70% in the third quarter and 45% in the first nine months of fiscal 2002 over the same periods in fiscal 2001. Compex's revenue increases resulted from volume increases in all markets, particularly Spain. Revenue from U.S. operations was up 2% in the third quarter and up 3% in the first nine months of fiscal 2002 compared to the same periods in fiscal 2001. Increases in revenue from direct rental or sale to patients of 5% in the third quarter and 7% in the first nine months resulted primarily from increased sales of units and supplies. Those increases were offset by declines in sales to medical product dealers and distributors as many of them converted some of their purchases to lower priced, often imported, units.

Gross profit was \$12,074,000 or 67.9% of revenue for the third quarter and \$34,529,000 or 67.2% of revenue for the first nine months of fiscal 2002, compared with \$10,349,000 or 68.2% of revenue for the third quarter and \$31,049,000 or 68.6% of revenue for the first nine months of fiscal 2001. The decline in the gross margin percentage resulted from continued growth of Compex revenue as a percent of total revenue and further reductions in the Compex gross margin percentage as a result of changes in product mix toward lower price sport and fitness products. Overall margins are expected to continue in the midsixties.

11

Selling, general and administrative expenses increased 20% to \$9,687,000 in the third quarter of fiscal 2002 from \$8,049,000 in fiscal 2001. As a percent of revenue, those expenses increased to 54% in the third quarter of fiscal 2002 from 53% in fiscal 2001. U.S. expenses for the third quarter included a charge of \$563,000 for accrued compensation payable to David B. Kaysen, who resigned as President and CEO of the Company effective March 31, 2002. For the nine months ended March 31, 2002, selling, general and administrative expenses increased 10% to \$26,180,000 from \$23,813,000 in fiscal 2001. As a percent of revenue, those expenses declined to 51% during the first nine months of fiscal 2002 from 53% in fiscal 2001. The decline in the nine-month period resulted from Compex expenses increasing at a rate slower than the related increase in its revenue as newer markets achieve significant growth. In the U.S., those expenses are essentially unchanged as a percent of revenue after adjusting for the effect of discontinuing amortization of goodwill as described in Note 2 to the financial statements.

Research and development expense decreased 4% to \$473,000 in the third quarter of fiscal 2002. In the nine months ended March 31, 2002, those costs increased 18% to \$1,576,000 from \$1,334,000 in fiscal 2001. The increase in the nine-month period reflects the cost of new product development activities both in the U.S. and Compex operations. The most significant project in the U.S. was the new ProMax TENS unit for which production started in October 2001. In Europe, three new products have been introduced in the last nine months. The Company anticipates that research and development expenses will remain relatively constant as a percentage of revenue in future periods.

Interest expense decreased 54% from \$313,000 in the third quarter of fiscal 2001

to \$144,000 in the third quarter of fiscal 2002 and decreased 45% from \$1,026,000 in the first nine months of fiscal 2001 to \$560,000 in fiscal 2002. The decreases resulted from lower interest rates and overall lower borrowings under the Company's credit facility. The Company expects interest expense to continue to decline with the lower overall balance of its indebtedness.

The provision for income taxes is 42% of income before taxes for the first nine months of fiscal 2002 compared to 43% for the same period of fiscal 2001. The Company operates in various countries in Europe as well as the United States. Some countries have higher tax rates than the United States as well as different rules on the deductibility of certain expenses and the availability of certain credits for taxes paid to other jurisdictions. The Company believes that 42% is a reasonable estimate of the effective rate for fiscal 2002 based on most recent estimates of expected sources of revenue and expenses for the entire year. The Internal Revenue Service has recently completed an examination of the Company's federal income tax returns for the years ended June 30, 1997 and 1998 and has proposed adjustments pursuant to such audit, most of which relate to the timing of revenue or expense recognition. The Company has filed a formal appeal of certain proposed adjustments and believes its provision for income taxes and related reserves are adequate.

As a result of the above activity, net income increased from \$853,000 in the third quarter of fiscal 2001 to \$1,029,000 in the third quarter of fiscal 2002. For the nine months ended March 31, 2002, net income increased to \$3,612,000 from \$2,806,000 during the same period in fiscal 2001. Diluted earnings per share increased from \$.08 to \$.09 for the third quarter and \$.26 to \$.32 per share for the nine month period.

12

LIQUIDITY AND CAPITAL RESOURCES

For the nine months ended March 31, 2002, the Company's operations provided cash of \$3,392,000, mainly from net income of \$3,612,000 plus depreciation and amortization and less the net increase in current assets. Prepaid expenses declined due to lower value added tax prepayments by Compex. Accounts receivable increased \$2,144,000, mainly from higher sales and slower collections for Compex. The decrease in accounts payable relates to timing differences and the payment of year-end accruals.

The Company used \$662,000 in investing activities for the first nine months of fiscal 2002 for net purchases of property and equipment, including clinical and rental equipment.

The Company's financing activities used \$1,715,000 of cash during the first nine months of fiscal 2002, mainly for the repayment of \$2,470,000 of long-term debt under its \$20,000,000 credit facility, less net borrowings of \$400,000 under that facility. Borrowings were used primarily to build inventories in connection with new product introductions. At March 31, 2002, a total of \$8,997,000 is outstanding under this facility, including \$400,000 of short-term debt under the revolving line of credit.

This credit facility has a maturity date of June 30, 2004, at which time all outstanding borrowings are to be repaid. The Company anticipates all or substantially all borrowings under this credit facility will be repaid prior to

the maturity date. If any borrowings are still outstanding at maturity, the Company believes that the agreement could be extended with the current financial institution or another facility put in place.

Managing receivables represents one of the biggest business challenges to the Company. The process of determining what products will be reimbursed by third party payors and the amounts to be paid for those products is very complex and the reimbursement environment is constantly changing. That risk is spread across many payors throughout the United States. The determination of an appropriate reserve for uncollectible accounts at the end of each reporting period is based on various factors including historical trends and relationships and experience with insurance companies or other third party payors. The Company believes that the reserve at March 31, 2002 is adequate to cover future losses on its receivables based on collection history and trends. The provision for uncollectible accounts recorded in the income statement may continue to fluctuate significantly from quarter to quarter as such trends change. The reserve was 31% of receivables at March 31, 2002 compared to 30% at June 30, 2001.

The Company has no material commitment for capital expenditures. The Company believes that available cash and borrowings under its credit line will be adequate to fund cash requirements for the current fiscal year and the foreseeable future.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to market risk from changes in the interest rates on certain of its outstanding debt. The outstanding loan balance under the \$20 million credit facility bears interest at a variable rate based on the bank's prime rate or LIBOR. Based on the average outstanding bank debt for the period ended March 31, 2002, a 100 basis point change in interest rates would not change interest expense by a material amount.

13

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In late January 2001, Rehabilicare was served with documents in connection with a product liability case brought in the California Superior Court for Solano County. Although Rehabilicare had no record of the proceedings, the action had progressed to the entry of a default judgment on January 11, 2001.

Rehabilicare appealed the default judgment to the California Court of Appeals in March 2001. On May 10, 2002, the appeals court overturned the default judgment holding that there was no valid complaint against Rehabilicare on file.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS - None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES - None

ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The annual meeting of shareholders of Rehabilicare was held on January 10, 2002. Shareholders holding 8,814,831 shares, or approximately 81.4% of outstanding shares, were represented at the meeting by proxy or in person. The only matter submitted at the meeting for vote by the shareholders was as follows:

a. Election of Directors

The following nominees were elected to serve as members of the Board of Directors until the annual meeting of shareholders in 2002 or until such time as a successor may be elected.

	In Favor	Withheld
Frederick H. Ayers	8,746,145	68,686
Richard E. Jahnke	8,740,280	74,551
David B. Kaysen	8,735,559	79 , 272
John H.P. Maley	8,739,168	75 , 663
Robert C. Wingrove	8,747,004	67,827

Mr. Kaysen subsequently resigned as an executive officer and director effective March 31, 2002.

14

ITEM 5. OTHER INFORMATION - None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- (a) Exhibits
 - 10.1 Separation Agreement dated March 31, 2002 between the Company and David B. Kaysen
- (b) Reports on Form 8-K

None filed during the quarter ended March 31, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REHABILICARE INC.

May 15, 2002 /s/ John H.P. Maley

Date John H.P. Maley

Chief Executive Officer

May 15, 2002 /s/ W. Glen Winchell

Date W. Glen Winchell

Vice President of Finance

(Principal Financial and Accounting Officer)